Compare McKesson Corporation (MCK) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs VF Corp — how do they compare? McKesson Corporation trades at $824.58 (market cap $97.35B), while VF Corp trades at $16.85 (market cap $6.62B). The key difference: McKesson Corporation is far larger — about 14.7× VF Corp's market cap, and VF Corp pays the higher dividend (2.13%). Which is the better fit depends on your goals.
| MCK | VFC | |
|---|---|---|
Market Cap | $97.35B | $6.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $21.55 |
52-Week Low | $659.01 | $11.66 |
Enterprise Value | $101.98B | $10.77B |
Dividend Yield | 0.39% | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
VFC trades at $16.78, down 1.18% on the day, with technical indicators showing a neutral to bearish short-term bias. The company reported mixed quarterly results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026, with revenue declining to $9.50 billion in 2025. Analyst sentiment is cautiously optimistic with a consensus price target of $19.33, while recent news highlights ongoing brand challenges and debt reduction efforts.
The outlook for VFC hinges on execution of its turnaround strategy, particularly revitalizing the Vans brand. Near-term catalysts include Q2 2026 earnings and continued debt management, but risks remain from weak consumer spending and competitive pressures. The stock offers potential upside to analyst targets if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
